4.4 Review

Prostate-specific antigen glycoprofiling as diagnostic and prognostic biomarker of prostate cancer

Journal

INTERFACE FOCUS
Volume 9, Issue 2, Pages -

Publisher

ROYAL SOC
DOI: 10.1098/rsfs.2018.0077

Keywords

prostate cancer; diagnostics; biomarkers; lectins; glycans; prostate-specific antigen

Categories

Funding

  1. Slovak Scientific Grant Agency VEGA [2/0137/18, 2/0090/16]
  2. Slovak Research and Development Agency [APVV 17-0300]
  3. ERC Proof of Concept grant [825586]
  4. Innovative Training Network [813120]
  5. ERDF [26240120007]
  6. European Research Council (ERC) [825586] Funding Source: European Research Council (ERC)

Ask authors/readers for more resources

The initial part of this review details the controversy behind the use of a serological level of prostate-specific antigen (PSA) for the diagnostics of prostate cancer (PCa). Novel biomarkers are in demand for PCa diagnostics, outperforming traditional PSA tests. The review provides a detailed and comprehensive summary that PSA glycoprofiling can effectively solve this problem, thereby considerably reducing the number of unnecessary biopsies. In addition, PSA glycoprofiling can serve as a prognostic PCa biomarker to identify PCa patients with an aggressive form of PCa, avoiding unnecessary further treatments which are significantly life altering (incontinence or impotence).

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available